<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36846">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01933321</url>
  </required_header>
  <id_info>
    <org_study_id>ALS and stem cell therapy</org_study_id>
    <nct_id>NCT01933321</nct_id>
  </id_info>
  <brief_title>Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <authority>Mexico: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the
      neurodegenerative process and stops the clinical progression of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no more extensive information
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of autologous intrathecal administration of hematopoietic stem cells in patients with ALS.</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of intrathecal administration of hematopoietic stem cells in patients with ALS.</measure>
    <time_frame>During the procedure and at 1st, 2nd, 3rd, 6th and 12 th month after the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Intrathecal autologous stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intrathecal autologous stem cell</intervention_name>
    <description>Mobilization and collection of stem cells for intravenous and intrathecal administration</description>
    <arm_group_label>Intrathecal autologous stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a confirmed diagnosis of ALS according to El Escorial criteria.
             Diagnosis-time less than four years.

          -  Over 18 years old. Forced vital capacity ≥ 40%.

          -  One year of evolution.

          -  Adequate nutritional state

        Exclusion Criteria:

          -  Severe bulbar ALS involucre.

          -  Inadequate nutritional status.

          -  Spondylotic myelopathy, or abnormalities in imaging study.

          -  Having concomitant neurological or psychiatric disease.

          -  Systemic disease with poor-control.

          -  History of treatment with steroids or immunoglobulins in the last year.

          -  Participate in the past three months in a Clinical Trial.

          -  History of malignancy or cancer today.

          -  Intracranial hypertension.

          -  Clinical suggestive data of infection in the site of lumbar puncture.

          -  Tracheostomy.

          -  Use of mechanical ventilation. Forced vital capacity less than 40%. HIV-seropositive
             or presence of antibodies against hepatitis B or C in the serological studies.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gomez-Almaguer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario &quot;Dr. José Eleuterio González&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose C Jaime-Pérez, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario &quot;Dr. José Eleuterio González&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Héctor R Martínez-Rodríguez, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario &quot;Dr. José Eleuterio González&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Servicio Hematología Hospital Universitario</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>September 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>Chair of Hematology</investigator_title>
  </responsible_party>
  <keyword>ALS, stem cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
